Fabrazyme (agalsidase beta)

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Fabry Disease

Conditions

Fabry Disease

Trial Timeline

Oct 1, 1999 → Dec 1, 2004

NCT ID

NCT00074971

About Fabrazyme (agalsidase beta)

Fabrazyme (agalsidase beta) is a phase 3 stage product being developed by Sanofi for Fabry Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00074971. Target conditions include Fabry Disease.

What happened to similar drugs?

9 of 20 similar drugs in Fabry Disease were approved

Approved (9) Terminated (4) Active (10)

✅agalsidase betaSanofiApproved

✅Fabrazyme (agalsidase beta)SanofiApproved

✅agalsidase betaSanofiApproved

✅AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + FexofenadineSanofiApproved

✅Agalsidase betaSanofiApproved

✅agalsidase beta (GZ419828) + agalsidase alfaSanofiApproved

✅Agalsidase betaSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00312767	Approved	Withdrawn	Apr 1, 2006	—	Fabry Disease
NCT00196716	Phase 2	Completed	Jun 1, 2003	Mar 1, 2007	Fabry Disease
NCT00074958	Phase 2	Completed	Oct 1, 2002	Jul 1, 2005	Fabry Disease
NCT00074971	Phase 3	Completed	Oct 1, 1999	Dec 1, 2004	Fabry Disease

Competing Products

20 competing products in Fabry Disease

See all competitors

Product	Company	Stage	Hype Score
Lucerastat	Idorsia	Phase 3	38
Fabrazyme (agalsidase beta)	Sanofi	Phase 2	35
Venglustat (GZ402671) + Placebo	Sanofi	Phase 3	44
Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta)	Sanofi	Phase 2	27
agalsidase beta	Sanofi	Approved	35
Tropicamide	Sanofi	Pre-clinical	26
Fabrazyme (agalsidase beta)	Sanofi	Approved	35
agalsidase beta	Sanofi	Approved	43
AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + Fexofenadine	Sanofi	Approved	43
Gabapentin + placebo	Sanofi	Phase 2	27
Agalsidase beta	Sanofi	Approved	43
GZ/SAR402671	Sanofi	Phase 2	35
agalsidase beta (GZ419828) + agalsidase alfa	Sanofi	Approved	35
Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + Migalastat	Sanofi	Phase 3	44
Iohexol	Sanofi	Phase 1	21
GZ/SAR402671	Sanofi	Phase 2	35
Fabrazyme (agalsidase beta)	Sanofi	Phase 2	35
Agalsidase beta	Sanofi	Approved	43
Fabrazyme (agalsidase beta) + Placebo	Sanofi	Approved	43
Agalsidase beta + Agalsidase beta	Sanofi	Phase 3	40